![Karl Anders Arne Linér](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karl Anders Arne Linér
Keine laufenden Positionen mehr
Karriereverlauf von Karl Anders Arne Linér
Ehemalige bekannte Positionen von Karl Anders Arne Linér
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Athera Biotechnologies AB
![]() Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Comptroller/Controller/Auditor | - | - |
RAYSEARCH LABORATORIES AB | Comptroller/Controller/Auditor | 01.01.2003 | - |
Statistik
International
Schweden | 3 |
Operativ
Comptroller/Controller/Auditor | 2 |
Sektoral
Technology Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
RAYSEARCH LABORATORIES AB | Technology Services |
Private Unternehmen | 1 |
---|---|
Athera Biotechnologies AB
![]() Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Health Technology |
- Börse
- Insiders
- Karl Anders Arne Linér
- Erfahrung